BCLC Stage D Hepatocellular Carcinoma

Known as: Barcelona Clinic Liver Cancer Stage D Hepatocellular Carcinoma 
End-stage hepatocellular carcinoma. Patients will receive symptomatic treatment. (HPB (Oxford) 2005; 7(1):35-41)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
01220112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial… (More)
Is this relevant?
2017
2017
BACKGROUND & AIM The need for a subclassification of Barcelona Clinic Liver Cancer (BCLC) intermediate-stage (BCLC B) has arisen… (More)
  • table 3
  • table 4
Is this relevant?
2017
2017
Transarterial chemoembolization (TACE) is recommended for patients with intermediate-stage (Barcelona Clinic Liver Cancer… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2013
Review
2013
BACKGROUND Sorafenib is an orally active multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma… (More)
Is this relevant?
2013
2013
UNLABELLED The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
With its approval in 2007 for advanced hepatocellular carcinoma (HCC), sorafenib became the first systemic agent with proven… (More)
  • figure 1
Is this relevant?
2011
2011
The Barcelona Clinic Liver Cancer (BCLC) staging system recommends first-line therapy for each tumor stage. We evaluated the… (More)
  • figure 1
  • table 1
  • table 2
  • table 2
  • figure 2
Is this relevant?